Candidaemia and antifungal therapy in a French University Hospital: Rough trends over a decade and possible links

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Sendid, Boualem ^a,b   Cotteau, Angélique ^b   François, Nadine ^a   D'Haveloose, Annie ^b   Standaert, Annie ^a   Camus, Daniel ^b   Poulain, Daniel ^a,b  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG COST; FRANCE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; INCIDENCE; PRESCRIPTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEROPREVALENCE; TEACHING HOSPITAL; UNIVERSITY HOSPITAL;

ANTIFUNGAL AGENTS; BIOLOGICAL EVOLUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; FLUCONAZOLE; FRANCE; FUNGEMIA; HUMANS; INCIDENCE; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 33745091248     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-80     Document Type: Article

References (29)

1. Hoyert DL, Kung HC, Smith BL: Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005, 53:1-48.
2. Pittet D: Nosocomial bloodstream infections. In Prevention and control of nosocomial infections 3rd edition. Edited by: Wenzel RP. Baltimore: Williams and wilkins; 1997:711-769.
3. Aubry-damon H, Lemanissier V, Lepoutre A, Coignard B, et al.: Prévalence des traitements antibiotiques à l'hôpital: résultats de l'enquête de prévalence nationale des infections nosocomiales 2001. Médecine & Maladies Infectieuses 2004, 34:S130-S169.
4. Berrouane YF, Herwaldt LA, Pfaller MA: Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999, 37:531-537.
5. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39:3254-3259.
6. Pfaller MA, Diekema DJ: Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40:3551-3557.
7. Wenzel RP: Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995, 20:1531-1534.
8. Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702.
9. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R: Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
10. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J, Lee-Yang W, Ciblak MA, Benjamin LE, Sanza LT, Huie S, Yeo SF, Brandt ME, Warnock DW: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.
11. Marr KA: Invasive Candida infections: the changing epidemiology. Oncology (Huntingt) 2004, 18:9-14.
12. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J: Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998, 24:206-216.
13. Wright WL, Wenzel RP: Nosocomial Candida. Epidemiology, transmission, and prevention. Infect Dis Clin North Am 1997, 11:411-425.
14. Cha R, Sobel JD: Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther 2004, 2:357-366.
15. Pfaller MA, Diekema DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10(Suppl 1): 11-23.
16. Meyer MH, Letscher-Bru V, Jaulhac B, Waller J, Candolfi E: Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system. J Clin Microbiol 2004, 42:773-777.
17. Blot S, Vandewoude K: Management of invasive candidiasis in critically ill patients. Drugs 2004, 64:2159-2175.
18. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
19. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D: Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
20. Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J, Leon-Regidor MA: Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004, 23:323-330.
21. Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27:781-788.
22. Richardson MD, Carlson P: Culture- and non-culture-based diagnostics for Candida species. In Candida and candidiasis Edited by: Calderone RA. Washington: ASM Press; 2002:387-394.
23. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M: International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997, 25:43-59.
24. Marr KA, Seidel K, White TC, Bowden RA: Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309-316.
25. Snydman DR: Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003, 123:500S-503S.
26. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D: Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002, 81:425-433.
27. Cagnoni PJ: Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002, 49(Suppl 1):81-86.
28. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73-85.
29. Baddley JW, Smith AM, Moser SA, Pappas PG: Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital. Diagn Microbiol Infect Dis 2001, 39:199-201.